Intelligent Bio Solutions Inc Stock Price, News & Analysis

Intelligent Bio Solutions (NASDAQ: INBS) reported preliminary, unaudited fiscal Q1 2026 revenue of over $1.0 million, a record for the company, representing approximately +32% sequential and +28% year‑over‑year growth for the quarter ended September 30, 2025.

Revenue strength was driven by new customer accounts and higher product demand: cartridge revenue +43% YoY and reader revenue +23% YoY. This marks the company’s third consecutive quarter of revenue growth and reflects an increasing share of higher‑margin consumables in the sales mix.

Results are preliminary and subject to adjustment; final Q1 2026 financials will be filed on Form 10‑Q during the week commencing November 10, 2025.

Intelligent Bio Solutions (Nasdaq: INBS) announced it added 33 new customer accounts in fiscal Q1 ended Sept 30, 2025, a 50% year-over-year increase, bringing total active accounts to over 480. Growth concentrated in maritime, transportation & logistics, electrical/electronic manufacturing, construction, and newly entered government administration sectors. About 91% of new accounts were first-time adopters; 9% were expansions. Regional expansion was strongest in the UK with distributor activity across Europe and the Middle East. The company positioned its fingerprint-based non-invasive drug screening to address a projected global market of $17.1B by 2029 (CAGR 15%).

Intelligent Bio Solutions (Nasdaq: INBS) announced a major new UK commercial contract on October 23, 2025 with a multinational industrial service provider that employs ~3,000 staff in the UK and Ireland and > 30,000 worldwide. The deployment is described as one of INBS's most significant UK commercial rollouts to date and moves the customer from urine-based third-party testing to INBS's rapid, non-invasive Intelligent Fingerprinting Drug Screening System.

The customer expects faster, less disruptive testing, shorter detection windows, improved employee experience, and on-site rapid results. INBS said this supports recurring cartridge revenue and follows prior deployments across transportation, construction, and mining; INBS reports > 480 accounts in 24 countries and 18 distribution partners. The company is pursuing FDA 510(k) clearance to expand U.S. workplace use beyond Forensic Use Only.

Intelligent Bio Solutions (Nasdaq: INBS) has provided an updated timeline for FDA 510(k) clearance of its Intelligent Fingerprinting Drug Screening System for opiate codeine detection. Following FDA feedback, the company will conduct additional clinical studies starting before year-end 2025, with completion expected in H1 2026. FDA clearance is anticipated in H2 2026.

The company's drug testing technology has already gained significant traction globally, with 450 accounts across 24 countries and 18 distribution partners. INBS continues to expand its presence in various industries including construction, transportation, logistics, and mining, while working to move beyond the Forensic Use Only market in the US.

Intelligent Bio Solutions (Nasdaq: INBS) provided an update on the FDA 510(k) clearance process for its Intelligent Fingerprinting Drug Screening System. Following their December 2024 submission, the FDA issued an Additional Information request in February 2025 with over 70 items to address.

After responding in August 2025, the FDA has requested new additional information requiring a new 510(k) notification submission. Being a first-of-its-kind sweat-based device, the extensive requirements are not uncommon for breakthrough technologies. The company expects to provide an investor update on the revised FDA clearance timeline within 10 days.

Meanwhile, INBS continues to expand its international business operations outside the U.S. market.

Intelligent Bio Solutions (Nasdaq: INBS) reported record-breaking monthly cartridge sales in July 2025, shipping 519 boxes containing over 12,500 cartridges, marking a 60% year-over-year increase. The company's fingerprint sweat-based drug testing system operates on a razor/razor blade business model, where cartridges serve as high-margin consumables.

INBS secured a significant multi-site contract in the transportation sector and is experiencing growing demand for its drug testing solutions. The company plans to expand beyond Forensic Use Only settings in the U.S. market during the second half of 2025, while focusing on leveraging its installed base to drive recurring cartridge sales.

Intelligent Bio Solutions (Nasdaq: INBS) reported its fiscal Q4 and full-year 2025 results, highlighting significant progress in its U.S. market expansion plans and operational performance. The company achieved 16% revenue growth both sequentially and year-over-year in Q4, reaching $843,884, driven by increased drug testing cartridge demand.

Key developments include advancement toward FDA 510(k) clearance for its opiate test system, expansion of its international presence to over 450 accounts across 24 countries, and a 24% year-over-year increase in cartridge sales for Q4. The company implemented operational efficiencies, launched multilingual support, and strengthened its intellectual property with a sixth U.S. patent.

Intelligent Bio Solutions (Nasdaq: INBS), a medical technology company focused on rapid, non-invasive testing solutions, has announced its participation in the upcoming Sidoti Micro-Cap Virtual Conference. The company's management team will present on Thursday, August 21, 2025, at 9:15 a.m. Eastern Time.

Investors can access the presentation through a webcast link and schedule one-on-one meetings with management through Sidoti representatives or KCSA Strategic Communications.

Intelligent Bio Solutions (Nasdaq: INBS) announced preliminary fiscal Q4 2025 results, highlighting 16% revenue growth both sequentially and year-over-year. The growth was driven by increased higher-margin cartridge sales and steady account expansion.

The company made significant operational progress, including submitting an FDA 510(k) application for its opiate test system for codeine. INBS also completed multilingual upgrades to its Intelligent Fingerprinting Drug Screening System and launched localized websites with enhanced CRM workflows across Europe, the Middle East, and Latin America.

Final audited results will be disclosed in the Annual Report on Form 10-K, expected during the week of August 11, 2025.